[{"address1": "480 Arsenal Way", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 393 4600", "website": "https://lyratherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 88, "companyOfficers": [{"maxAge": 1, "name": "Dr. Harlan W. Waksal M.D.", "age": 71, "title": "Executive Chairman", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 210060, "exercisedValue": 0, "unexercisedValue": 109541}, {"maxAge": 1, "name": "Mr. Jason  Cavalier", "age": 51, "title": "CFO, Treasurer & Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 464108, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ray  Knox", "title": "Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ronan P. O'Brien J.D.", "age": 51, "title": "Chief Legal Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Vineeta  Belanger Ph.D.", "title": "Senior Vice President of Clinical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Richard Ph.D.", "age": 66, "title": "Senior Vice President of Technical Operations", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 366742, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Kern M.D.", "title": "Chief Clinical Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gloria  Cosgrove", "title": "Senior Vice President of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Allison  Nance", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elazer R. Edelman FACC, M.D., Ph.D.", "age": 67, "title": "VP of Finance & Risk", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.2007, "open": 0.2008, "dayLow": 0.1924, "dayHigh": 0.2078, "regularMarketPreviousClose": 0.2007, "regularMarketOpen": 0.2008, "regularMarketDayLow": 0.1924, "regularMarketDayHigh": 0.2078, "beta": -0.036, "forwardPE": -0.2068783, "volume": 1664369, "regularMarketVolume": 1664369, "averageVolume": 2036111, "averageVolume10days": 2291910, "averageDailyVolume10Day": 2291910, "bid": 0.1956, "ask": 0.1994, "bidSize": 100, "askSize": 100, "marketCap": 12796961, "fiftyTwoWeekLow": 0.163, "fiftyTwoWeekHigh": 6.79, "priceToSalesTrailing12Months": 8.699497, "fiftyDayAverage": 0.21222, "twoHundredDayAverage": 1.007145, "currency": "USD", "enterpriseValue": -3505029, "floatShares": 41706340, "sharesOutstanding": 65457600, "sharesShort": 1837563, "sharesShortPriorMonth": 2378932, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.028099999, "heldPercentInsiders": 0.006, "heldPercentInstitutions": 0.59751, "shortRatio": 0.71, "shortPercentOfFloat": 0.035, "impliedSharesOutstanding": 67198704, "bookValue": 0.315, "priceToBook": 0.6206349, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -97612000, "trailingEps": -1.49, "forwardEps": -0.74, "enterpriseToRevenue": -2.383, "enterpriseToEbitda": 0.052, "52WeekChange": -0.96171427, "SandP52WeekChange": 0.24176979, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "LYRA", "underlyingSymbol": "LYRA", "shortName": "Lyra Therapeutics, Inc.", "longName": "Lyra Therapeutics, Inc.", "firstTradeDateEpochUtc": 1588339800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e0a4f15e-34ef-3087-b120-b47efafe701f", "messageBoardId": "finmb_142648423", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.1955, "targetHighPrice": 2.0, "targetLowPrice": 0.5, "targetMeanPrice": 1.25, "targetMedianPrice": 1.25, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 51626000, "totalCashPerShare": 0.789, "ebitda": -67039000, "totalDebt": 35324000, "quickRatio": 3.452, "currentRatio": 3.641, "totalRevenue": 1471000, "debtToEquity": 171.318, "revenuePerShare": 0.023, "returnOnAssets": -0.42294, "returnOnEquity": -1.8617901, "grossProfits": -48199000, "freeCashflow": -45860500, "operatingCashflow": -77717000, "revenueGrowth": -0.642, "operatingMargins": -49.42564, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]